Inclusion criteria | |
1. 1–17 years of age | |
2. Acute peripheral unilateral facial nerve palsy | |
3. Symptom duration < 72 h | |
4. Signed informed consent | |
Exclusion criteria | |
1. Head trauma < 1 month | |
2. Central facial palsy | |
3. Malformations of the head and neck | |
4. Conditions incompatible with corticosteroid treatment (arterial hypertension, diabetes mellitus type 1, psychiatric disorder, active or latent tuberculosis, intolerance of lactose) | |
5. Current or past oncological diagnosis | |
6. Other serious medical conditions (meningitis, encephalitis, stroke) | |
7. Acute otitis media | |
8. Signs of herpes simplex or varicella zoster infection (vesicles in the ear region) | |
9. Pregnancy or breastfeeding | |
10. Use of any systemic or inhaled corticosteroids within 2 weeks prior symptom onset | |
11. Immunization with live vaccine < 1 month prior onset of symptoms | |
12. Requirement of live vaccine within 2 months from start of experimental treatment (prednisolone/placebo) | |
13. Evaluation of primary endpoint at 12 months not feasible for any reason | |
14. Previously included into the FACE study |